论文部分内容阅读
目的:评价复方苦参注射液联合化疗治疗晚期大肠癌的疗效与安全性。方法:采用计算机检索Cochrane Central、Pub Med、Embase、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、维普中文科技期刊全文数据库(VIP)、万方数据库文献,筛选复方苦参注射液联合化疗治疗晚期大肠癌的随机对照试验,评价纳入研究的质量,提取资料,用Rev Man 5.3软件进行Meta分析。结果:共纳入12项研究含894例患者。Meta分析结果:与单纯化疗组比较,联合治疗组能提高患者近期有效率,改善生活质量,并降低骨髓抑制、胃肠道反应、肝功能损伤及神经毒性反应,差异均有统计学意义(P<0.05),但未降低血小板减少发生率(P>0.05)。结论:复方苦参注射液联合化疗可提高晚期大肠癌的近期有效率,改善生活质量并降低化疗毒副作用,但纳入研究质量不高,结论需要更多高质量、大样本的RCT进一步验证。
Objective: To evaluate the efficacy and safety of compound Kushen injection combined with chemotherapy in the treatment of advanced colorectal cancer. Methods: Cochrane Central, Pub Med, Embase, CBM, CNKI, VIP and Wanfang database were searched by computer. Liquid combined chemotherapy for advanced colorectal cancer randomized controlled trials to evaluate the quality of the included studies, data extraction, Meta-analysis using Rev Man 5.3 software. Results: A total of 12 studies included 894 patients. Meta analysis: Compared with the chemotherapy alone group, the combination therapy group can improve the patient’s recent efficiency, improve the quality of life, and reduce bone marrow suppression, gastrointestinal reactions, liver damage and neurotoxicity, the difference was statistically significant (P <0.05), but did not reduce the incidence of thrombocytopenia (P> 0.05). Conclusion: Compound Kushen injection combined with chemotherapy can improve the short-term efficiency of advanced colorectal cancer, improve the quality of life and reduce the side effects of chemotherapy. However, the quality of the included studies is not high, so more high-quality, large sample RCTs are needed for further validation.